FOREST ANNOUNCES FEDERAL COURT UPHOLDS LEXAPRO PATENT

Forest Laboratories, Inc. said that the U.S. District Court for the District of Delaware has determined that the U.S. patent covering escitalopram, the active ingredient in Lexapro, is both valid, enforceable and infringed by Ivax/Teva's proposed generic product, thereby confirming Forest's and Lundbeck's patent rights for Lexapro, which expire in March 2012.
Drug Newswire